TIL
Instil Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.58
−1.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 24.0K | 534.0K | — | — | 6.0M |
| Gross Profit | (24.0K) | (534.0K) | — | — | (6.0M) |
| Operating Expenses | |||||
| R&D Expense | 13.6M | 10.0M | 11.8M | 39.6M | 141.1M |
| SG&A Expense | 22.4M | 27.2M | 44.2M | 47.6M | 62.2M |
| General & Admin Expense | 22.4M | 27.2M | 44.2M | 47.6M | 62.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 169.0K | 15.2M | 17.5M | 72.0M | (3.1M) |
| Total Operating Expenses | 36.2M | 52.4M | 73.5M | 159.2M | 200.2M |
| Cost and Expenses | 36.2M | 52.9M | 73.5M | 159.2M | 206.2M |
| Operating Income (EBIT) | (36.2M) | (52.9M) | (73.5M) | (159.2M) | (206.2M) |
| Non-Operating | |||||
| Interest Income | 2.9M | 3.9M | 7.0M | 8.9M | 3.7M |
| Interest Expense | 5.5M | 5.8M | 9.0M | 5.2M | 1.9M |
| Net Interest Income | (2.5M) | (2.0M) | (2.0M) | 3.7M | 1.8M |
| Other Non-Op Income/Expense | 5.9M | (18.5M) | (594.0K) | 3.1M | (19.1M) |
| Non-Operating Income (excl Interest) | (6.3M) | 12.6M | (7.4M) | (7.3M) | 17.2M |
| EBT (Pre-Tax Income) | (30.3M) | (71.4M) | (74.1M) | (156.1M) | (225.3M) |
| Income Tax Expense | — | — | — | — | (2.1M) |
| Bottom Line | |||||
| Net Income | (30.3M) | (71.4M) | (74.1M) | (156.1M) | (223.2M) |
| Earnings from Cont. Ops | (30.3M) | (71.4M) | (74.1M) | (156.1M) | (223.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (30.3M) | (71.4M) | (74.1M) | (156.1M) | (223.2M) |
| Per Share | |||||
| Basic EPS | ($4.47) | ($10.70) | ($11.39) | ($24.00) | ($34.46) |
| Diluted EPS | ($4.47) | ($10.70) | ($11.39) | ($24.00) | ($34.46) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 6.8M | 6.7M | 6.5M | 6.5M | 6.5M |
| Diluted Shares Outstanding | 6.8M | 6.7M | 6.5M | 6.5M | 6.5M |
| Profitability Metrics | |||||
| EBITDA | (29.6M) | (65.0M) | (62.5M) | (147.1M) | (217.4M) |
| D&A | 279.0K | 534.0K | 3.6M | 4.8M | 6.0M |
| EBIT | (29.9M) | (65.5M) | (66.1M) | (151.9M) | (223.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026